Barclays keeps Amgen at equal-weight and lifts price target to $400
Barclays maintained its equal-weight rating on Amgen and raised its price target from $380 to $400 a share, Dow Jones Newswires reported.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at Barclays kept their rating on Amgen shares at equal-weight, which corresponds to a neutral view on the stock.
At the same time, the bank raised its price target for the shares from $380 to $400 each, according to Dow Jones Newswires, citing Benzinga ratings data.
why it matters
Rating changes of this kind usually affect sentiment around a single company and rarely shift the broader market picture. For Amgen investors, the direction of analyst forecasts is the key point.
tags
instruments
sources
- Amgen Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 21 October 2026 at 13:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗